SCHEMBL9958159

SCHEMBL9958159

Cc1cccc(-c2cc(-c3cccc(C)c3)nc(-c3cc[c]cc3)n2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.50
IDO1 P14902 1/20 0.47
METAP2 P50579 1/20 0.47
XDH P47989 1/20 0.45
CTSS P25774 1/20 0.44
CTSK P43235 1/20 0.44
BCHE P06276 1/20 0.44
ACHE P22303 1/20 0.44
SDHB P21912 1/20 0.43
DPP4 P27487 1/20 0.42
KDM4E B2RXH2 3/20 0.42
NPC1 O15118 2/20 0.42
MEN1 O00255 2/20 0.41
ALDH1A1 P00352 2/20 0.41
LMNA P02545 2/20 0.41
MAPT P10636 2/20 0.41
HPGD P15428 2/20 0.41
KMT2A Q03164 2/20 0.41
GLA P06280 1/20 0.41
ADORA2A P29274 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4546907 0.85 RAB9A (0.56) RAB9AIDO1METAP2XDHBCHE
SCHEMBL4546906 0.85 RAB9A (0.66) RAB9AIDO1METAP2XDHCTSS
SCHEMBL4546919 0.84 ENPP3 (0.56) RAB9AIDO1METAP2XDHBCHE
SCHEMBL16201494 0.84 MEN1 (0.58) RAB9AIDO1METAP2XDHDPP4
SCHEMBL4546972 0.82 RAB9A (0.53) RAB9AIDO1METAP2XDHDPP4
SCHEMBL4546922 0.82 RAB9A (0.53) RAB9AIDO1METAP2XDHDPP4
SCHEMBL10128354 0.82 RAB9A (0.53) RAB9AIDO1METAP2XDHDPP4
SCHEMBL4546911 0.82 RAB9A (0.53) RAB9AIDO1METAP2XDHDPP4
SCHEMBL4546913 0.82 RAB9A (0.61) RAB9AIDO1METAP2XDHCTSS
SCHEMBL16376452 0.81 MEN1 (0.58) RAB9AIDO1METAP2DPP4KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9624193-B2 Cyclic azine derivatives, processes for producing these, and organic electroluminescent element containing these as component TOSOH CORPORATION (JP) 2017-04-18 US disclosed
US-20150329544-A1 CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT TOSOH CORPORATION (JP) 2015-11-19 US disclosed
US-9120773-B2 Cyclic azine derivatives, processes for producing these, and organic electroluminescent element containing these as component TOSOH CORPORATION (JP) 2015-09-01 US disclosed
EP-2818462-A1 Cyclic azine derivatives, processes for producing these, and organic electrolumiscent element containing these as component TOSOH CORPORATION (JP) 2014-12-31 EP disclosed
US-20120214993-A1 CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT SAGAMI CHEMICAL RESEARCH INSTITUTE, (JP) 2012-08-23 US disclosed
EP-2468731-A1 CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT Tosoh Corporation (JP) 2012-06-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150329544-A1 CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT CPNE4, EPB41, AZI2 RAB9A 1136/4885IDO1 2249/4885METAP2 4396/4885
US-20120214993-A1 CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT CPNE4, EPB41, AZI2 RAB9A 1136/4885IDO1 2249/4885METAP2 4396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.